Trials
3 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Fatigue Related to Cancer Treatment (2 trials), Colon Cancer (2 trials), Breast Cancer, Fatigue
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will:…”In the company’s words, NCT07669467 on ClinicalTrials.gov
Other drugs for Colon Cancer
- DostarlimabGSK · Phase 3
- XLJDOD compound granuleJiangsu Famous Medical Technology Co., Ltd. · Phase 3
- RC148RemeGen · AbbVie · Phase 2/3
- INCA33890Incyte Corporation · Phase 3
- CalderasibMerck & Co. · Phase 3
- PF-08634404Pfizer · 3SBio · Phase 3
Coming up1
- 31 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Oct 2026 | Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | |
| Phase 3Recruiting | 31 Oct 2026 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy. | |
| Phase 3Recruiting | 31 Mar 2027 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy | |
| Phase 3Completed | 25 Apr 2026 | A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy | |
| Phase 1/2Completed | 10 Aug 2022 | Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026